ADCT vs. MRSN, CCCC, NKTR, ALEC, VERV, DAWN, COLL, ABCL, LQDA, and TYRA
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Mersana Therapeutics (MRSN), C4 Therapeutics (CCCC), Nektar Therapeutics (NKTR), Alector (ALEC), Verve Therapeutics (VERV), Day One Biopharmaceuticals (DAWN), Collegium Pharmaceutical (COLL), AbCellera Biologics (ABCL), Liquidia (LQDA), and Tyra Biosciences (TYRA). These companies are all part of the "medical" sector.
ADC Therapeutics (NYSE:ADCT) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
Mersana Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ADC Therapeutics had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.59 beat ADC Therapeutics' score of 0.65 indicating that Mersana Therapeutics is being referred to more favorably in the news media.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ADC Therapeutics currently has a consensus price target of $7.25, suggesting a potential upside of 111.99%. Mersana Therapeutics has a consensus price target of $6.29, suggesting a potential upside of 193.72%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than ADC Therapeutics.
Mersana Therapeutics received 194 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 65.78% of users gave Mersana Therapeutics an outperform vote while only 65.00% of users gave ADC Therapeutics an outperform vote.
ADC Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
ADC Therapeutics has a net margin of -330.17% compared to Mersana Therapeutics' net margin of -352.01%. Mersana Therapeutics' return on equity of -260.65% beat ADC Therapeutics' return on equity.
Summary
Mersana Therapeutics beats ADC Therapeutics on 13 of the 18 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
